Scribe Therapeutics, Inc. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Scribe Therapeutics completed an upsized IPO on July 24, 2026, priced at $15/share, raising $155.5M gross proceeds (including Sanofi concurrent private placement). The company initiated first-in-human Phase 1 trial of STX-1150 in Australia (epigenetic silencing for LDL-C lowering) and secured $25.7M non-dilutive CIRM grants for STX-1200 (Lp(a)) and STX-1400 (triglycerides). Pro forma cash runway extends into H1 2029.
Why this rating
IPO validates clinical-stage biotech; capital raise + grants substantially extend runway for multiple programs. Meaningful for early-stage company but pre-revenue stage with unproven candidates.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.46% over 4 hrs, n=19).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $30.90 ▲ 0.00% | at our read · unknown $30.90 | +10 min · unknown $30.90 ▲ 0.00% | +30 min · unknown $30.90 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.